Effect of electromagnetic form of Melilotus officinalis extract on dermal wound healing in diabetic mice

Pharmacologyonline

Volumn 2, Issue , 2008, Pages 246-254

  Farzamfar, Bardia ^a   Minaie, Bagher ^b   Mobtaker, Mahdieh ^c   Salari, Pooneh ^c   Khorasani, Reza ^c   Baeeri, Maryam ^c   Fallah, Saeed ^c   Abdollahi, Mohammad ^d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidants; Diabetes; Diabetic ulcer; Electromagnetic; Melilotus officinalis

Indexed keywords

MELILOTUS EXTRACT; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROMAGNETIC FIELD; EXPERIMENTAL DIABETES MELLITUS; HAIR GROWTH; HISTOPATHOLOGY; MELILOTUS OFFICINALIS; MOUSE; NONHUMAN; SCAR FORMATION; SKIN INJURY; SKIN ULCER; STREPTOZOCIN DIABETES; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING;

EID: 52649133914     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Larijani, B., Hasani Ranjbar, S. Overview of diabetic foot; novel treatments in diabetic foot ulcer. DARU 2008; 16:1-6.
2. Consoli A. Chronic venous insufficiency: an open trial of FLEBS Crema. Minerva Cardioangiol 2003; 51(4):411-6.
3. Cataldi A, Gasbarro V, Viaggi R, Soverini R, Gresta E, Mascoli F. Effectiveness of the combination of alpha tocopherol, rutin, melilotus, and centella, asiatica in the treatment of patients with chronic venous insufficiency. Minerva Cardioangiol 2001; 49(2):159-63.
4. Fö1di-Börcsök E, Bedall F, Rahlfs VW. The anti-inflammatory and anti-edematous effects of coumarins from Melilotus officinalis. Arzneimittelforschung 1971; 21(12):2025-30.
5. Asres A, Eder U, Bucar F. Studies on the anti-inflammatory activity of extracts and compounds from the leaves of Melilotus elegans. Ethiopian Pharmaceutic J 2000; 18: 15-24.
6. Pleşca-Manea L, Pǎrvu AE, Pǎvu M, Taǎmas M, Buia R, Puia M. Effects of Melilotus officinalis on acute inflammation. Phytother Res 2002; 16(4):316-9.
7. Pastura G, Mesiti M, Saitta M, Romeo D, Settineri N, Maisano R, Petix M, Giudice A. Lymphedema of the upper extremity in patients operated for carcinoma of the breast: clinical experience with coumarinic extract from Melilotus officinalis. Clin Ter 1999; 150(6):403-8.
8. Vettorello G, Cerreta, G, Derwish A, Cataldi A, Schettino A, Occhionorelli S, Donini I. Contribution of a combination of alpha and beta benzopyrones, flavonoids and natural terpenes in the treatment of lymphedema of the lower limbs at the 2nd stage of the surgical classification. Minerva Cardioangiol 1996; 44(9):447-55.
9. Podkolzin AA, Dontsov VI, Sychev IA, Kobeleva Glu, Kharchenko ON. Immunocorrecting, antianemia, and adaptogenic effects of polysaccharides from Melilotus officinalis. Biull Eksp Biol Med 1996; 121(6):661-3.
10. Abdollahi M, Farzamfar B, Salari P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Evaluation of acute and sub-chronic toxicity of Semelil (ANGIPARSTM), a new phytotherapeutic drug for wound healing in rodents. Daru 2008; 16: 7-14.
11. Farzamfar B, Abdollahi M, Ka'abinejadian S, Heshmat R, Shahhosseiny MH, Novitsky YA, Farhadi M. Sub-chronic toxicity of a novel herbal-based formulation (Semelil) on dogs. Daru 2008; 16: 15-19.
12. Khorram Khorshid HR, Sadeghi B, Heshmat F, Abdollahi M, Salari P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARSTM). Daru 2008; 16: 20-24.
13. Heshmat F, Mohammad K, Mohajeri Tehrani MR, Tabatabaie Malazy O, Keshtkar AA, Gharibdoust F, Larijani B. Assessment of maximum tolerated dose of a new herbal drug, Semelil (ANGIPARSTM) in patients with diabetic foot ulcer: a phase I clinical trial. 2008; 16: 25-30.
14. Masoompour SM, Bagheri ME, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARSTM, a new herbal drug on diabetic foot ulcer: a phase 2 clinical study. 2008; 16: 31-34.
15. Larijani B, Heshmat R, Bahrami A, Delshad H, Ranjbar Omrani G, Mohammad K, Heidarpour R, Mohajeri Tehrani MR, Karnali K, Farhadi M, Gharibdoust F, Madani SH. Effects of intravenous Semelil (ANGIPARSTM) on diabetic foot ulcers healing: a multicenter clinical trial. 2008; 16: 35-40.
16. Bahrami A, Karnali K, Ali-Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorshid HR, Gharibdoust F, Madani SH, Larijani B. Clinical application of oral form of ANGIPARSTM and in combination with topical form as a new treatment for diabetic foot ulcers: a randomized clinical trail. 2008; 16: 41-48.
17. Shamimi-Nouri K, Heshmat R, Karimian R, Nasli E, Larijani B, Novitsky YA, Farhadi M, Gharibdoust F. Intravenous Semelill (ANGIPARSTM) as a novel therapy for pressure ulcers: a randomized clinical trial. 2008; 16: 49-53.
18. Shamimi-Nouri K, Karimian R, Nasli E, Kamali K, Chaman R, Farhadi M, Madani SH, Larijani B, Khorram Khorshid HR. Topical application of Semelil (ANGIPARSTM) in treatment of pressure ulcers: a randomized clinical trial. 2008; 16: 54-57.
19. Masters KSB, Leibovich SJ, Belem P, West JL, Poole-Warren LA. Effects of nitric oxide releasing poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice. Wound Rep Reg 2002; 10: 286-94.
20. Rahimi R., Nikfar S., Larijani B., Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005, 59(7): 365-373.
21. Hirakawa T, Okawa M, Kinjo J, Nohara T. A new oleanene glucuronide obtained from the aerial parts of Melilotus officinalis. Chem Pharm Bull (Tokyo) 2000; 48(2):286-7.